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Colorectal cancer (CRC) has become one of the most common fatal cancers. CRC tumorigenesis is a complex process involving
multiple genetic changes to several sequential mutations or molecular alterations. P53 is one of the most signiﬁcant genes; its
mutations account for more than half of all CRC. Therefore, understanding the cellular genes that are directly or indirectly related
top53is particularlycrucialfor investigatingCRCtumorigenesis.Inthisstudy,ap53-related ribosomalprotein,ribosomalprotein
S19 (RPS19), obtained from the feces of CRC patients is evaluated by using speciﬁcally quantitative real-time PCR and knocked
down in the colonic cell line by gene silencing. This study found that CRC patients with higher expressions of RPS19 in their feces
had a better prognosis and consistent expressions of RPS19 and BAX in their colonic cells. In conclusion, the potential mechanism
of RPS19 in CRC possibly involves cellular apoptosis through the BAX/p53 pathway, and the levels of fecal RPS19 may function as
a prognostic predictor for CRC patients.
1.Introduction
Despiteprogressinreducingtheincidenceandmortalityrate
and improving patient survival, human cancers still account
for numerous deaths [1]. Colorectal cancer (CRC) has be-
come one of the most common fatal cancers, involving
a complex process with multiple genetic changes [2–4].
This molecular heterogeneity possibly results from multi-
ple sequential mutations or molecular alterations during
tumorigenesis [5]. Therefore, the identiﬁcation of CRC-re-
lated genes will assist in cancer prevention, detection, and
prognostic prediction [6–8].
One important tumor suppressor, p53, is known to pre-
vent cancer, but is also involved in CRC progression [9, 10].
M u t a t i o n so fp 5 3a c c o u n tf o rm o r et h a nh a l fo fa l lC R C s ,
particularly in patients at the more advanced stages [11].
Numerous cellular genes are also out of control because
of the abnormal p53 expression during tumor progression
[12, 13]. For example, the p53-related ribosomal proteins
(RPs) were identiﬁed as cancer-related molecules [14, 15],
indicating that the oncogenic potential of RPs result from
the relationship between p53 and RPs [16–18]. Moreover,
the p53-inducible modulator RPS27-like (RPS27L), which
responds to genotoxic stress, was recently evaluated in CRC
[19].
Feces can serve as the material for detecting genetic al-
terations in CRC [20–22]. Numerous ribosomal proteins2 ISRN Gastroenterology
Table 1: Clinical characteristics of CRC patients.
Variable No. of cases Level of fecal RPS19 (%)
(≥2.76 × 10−5) P
Age (yr)∗
0.448 <64.7 47 27 (57.4)
≥64.7 54 35 (64.8)
Gender
0.140 Male 69 39 (56.5)
Female 32 23 (71.9)
Depth of invasion
0.303 T1 + T2 15 11 (73.3)
T3 + T4 86 51 (59.3)
Lymphatic invasion
0.068 N0 53 37 (69.8)
N1 + N2 + N3 48 25 (52.1)
Distant metastasis
0.183 No 84 54 (64.3)
Yes 17 8 (47.1)
Tumor size (cm)∗∗
0.682 <4.7 61 36 (59.0)
≥4.7 38 24 (63.2)
CEA (ng/mL)∗∗
0.907 ≤5 61 37 (60.7)
>5 37 22 (59.5)
CA19-9 (U/mL)∗∗
0.829 <37 74 45 (60.8)
≥37 24 14 (58.3)
∗mean age of 101 patients, 64.7 ys (range, 37.3–89.5). ∗∗available cases in tumor size, 99; in serum CEA and CA19-9 determinant, 98.
are signiﬁcantly expressed in the feces of CRC patients
[23]. In this study, p53-related RPS19 of CRC was further
evaluated. Other studies have reported on the developmental
abnormalities resulting from a RPS19 deﬁciency through the
activation of the p53 protein family [24]. First, the clinical
signiﬁcance of RPS19 in feces was evaluated from the stool
samples of CRC patients using speciﬁcally, quantitative real-
time PCR (qRT-PCR). Then, the functional importance of
RPS19 was addressed by silencing its expression in colonic
cells. In this context, we explored the possible cell fate of
changing the RPS19 expression in colonic cells, which could
aﬀect CRC patients’ survival.
2.MaterialsandMethods
2.1. Patients. Solid fecal samples of 101 CRC patients
(nmale = 69; nfemale = 32) from the Cathay General Hos-
pital and the Taipei Veterans General Hospital were obtained
before surgery or application of chemotherapy, with IRB-
approved informed consent. Follow-up data were obtained
prospectively, and the mean follow-up time was 44.1 months
(SD, 29.0; median, 37.8). Patients’ initial tumor stage and
additional clinical information are listed in Table 1. Patients
with distant metastasis were routinely conﬁrmed by abdom-
inal computed tomography.
2.2. Total RNA Extraction and Reverse Transcription Reaction.
The HCT116 cell line was cultured in Dulbecco’s modiﬁed
Eagle’s medium with 5mM of glutamine according to rou-
tinecultureprocedures.RNAfromthiscelllinewasextracted
using the Easy Pure Total RNA Mini Kit (Bioman, Taiwan)
and reverse transcribed for single-stranded cDNAs using an
oligo(dT)12 primer with the ABI Reverse Transcriptase kit
(ABI, USA), according to the manufacturer’s protocols [25].
FecalRNA waspreparedandreverse transcribed asdescribed
in our previous reports [22]. In brief, synthesized cDNA
could be used directly in the following quantitative PCR
analyses.
2.3. Quantitative Real-Time PCR (qRT-PCR). The quanti-
tations of RPS19 (NM001022), BAX (NM138764), and 18s
rRNA (X03205) in fecal cDNA were performed using a
TaqMan probe (probe no. 87 for RPS19, no. 55 for BAX,
and no. 77 for 18s rRNA) from the Human Universal
ProbeLibrary(RocheDiagnostics,Germany).The18srRNA
served as a housekeeping gene. Generally, each run of fecal
samples must include the human reference cDNA (Clontech,
USA) as standard to avoid errors because of run-to-run
diﬀerences in RNA quantity. The primer sequences for these
quantitations are listed in Table 2.ISRN Gastroenterology 3
Table 2: Primers’ sequences and universal probe numbers for qRT-PCR analysis.
Gene name Primer sequence∗ Probe no.
RPS19 F: 5 -TCAGGGACAAAGAGATCTGGA-3 
87 R: 5 -CATGGTTTGTTCTAATGCTTCTTG-3 
BAX F: 5 -CAAGACCAGGGTGGTTGG-3 
55 R: 5 -CACTCCCGCCACAAAGAT-3 
18s RNA F: 5 -CTCAACACGGGAAACCTCAC-3 
77 R: 5 -CGCTCCACCAACTAAGAACG-3 
∗F, forward; R, reverse; Probe no., from the “Human Universal Probe Library” of Roche Diagnostics, Mannheim, Germany.
CRC patient NP01NP02 03 07 10 01 04 02 06 11 08 05 09
––C CC AA BB B DD D








Figure 1: Six diﬀerentially expressed p53-associated ribosomal proteins in feces of CRC patients. Diﬀerentially expressed genes with statistic
signiﬁcance (P<0.05) are grouped by average-linkage hierarchical clustering. Each row represents a gene and each column is a sample.
Group L, ﬁve patients (one at Dukes’ stage B, one at stage C, and three at stage D). Group E, six patients (two at Dukes’ stage A, two at
stage B, and two at stage C) and two normal control pools (NP01 and NP02). NP01, pooled by two healthy men; NP02, pooled by three
healthy women. A region cluster depicts the genes based on the similarity between their expressions in cases. High expression is shown in
deep yellow, low expression in blue. Arrow indicates RPS19.
2.4. Lentivirus-Mediated RNA Interference (RNAi) of RPS19.
The lentiviral construct encoding the siRPS19 hairpin
(pLKO.1-RPS19:TRCN0000074915) for gene silencing
(shRPS19) was obtained from the National RNAi Core
Facility located at the Institute of Molecular Biology/Ge-
nomic Research Center, Academia Sinica, Taipei Taiwan.
Additionally, the control (shLuc) for the lentivirus was
pLKO.1-Luc (TRCN0000072246), and the infection of each
lentivirus into colonic cells was performed according to
our previous report [20]. The change in the expression
of target RPS19 was quantiﬁed by qRT-PCR as previously
described and immunodetected using western blotting
as the routine procedure with minor modiﬁcations [25].
Brieﬂy, 5μg of protein was mixed with the reducing agent
NuPAGE SDS sample buﬀer (Life Technologies, Carlsbad,
CA, USA), denatured for 10min at 95◦C, separated by a
12% SDS-PAGE, blotted onto a polyvinylidene diﬂuoride
membrane (Millipore, Billerica, MA, USA), and probed with
mouse anti-human RPS19 (1:1000; sc-100836; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or rabbit anti-hu-
man actin (1:500; sc-1616-R; Santa Cruz Biotechnology)
following standard procedures. The blots were then incu-
bated with anti-mouse (for RPS19) or anti-rabbit (for actin)
secondary antibodies (0.2μg/mL) conjugated to horseradish
peroxidase. All western blots were developed using the
Western Blot Chemiluminescence Reagent (PerkinElmer
Life and Analytical Sciences, Waltham, MA, USA) according
to the manufacturer’s instructions.
2.5. Statistical Analysis. The overall survival probabilities
were estimated using the Kaplan-Meier method and com-
pared with the log-rank test using SPSS 13.0 software
(SPSS). The MedCalc software statistical package was used
to generate a receiver operating characteristic (ROC) curve.
Signiﬁcance was set at P<0.05.
3. Results
Over 40 ribosomal or ribosomal-associated genes were
clustered due to their signiﬁcantly diﬀerential expressions
(P<0.05) in the feces of CRC patients from our previous
report [23]. Notably, six p53-associated RPs, including
two large- and four small-ribosomal protein transcripts,
were clustered by the average-linkage hierarchical clustering
method (Figure 1). The 11 CRC patients and two distinct
normal pools could be classiﬁed into two groups (E and L).
First, 80% (4 of 5) of patients of the L group were in the late
Dukes’ stages (one in Dukes’ stage C and three in stage D),
and, with the exception of RPS6 (NM001010), their genes
were downregulated. Conversely, RPS27L (NM015920),
RPS7 (NM001011), and RPL26 (NM000987) were clustered
together due to their increasing expressions in the feces
of those in group E, which comprised mostly early-stage
patients (67%, 4 of 6) and normal controls.
TheclinicalsigniﬁcancesofRPS19werefurtheranalyzed.
The mRNA levels of RPS19 in the feces of CRC patients




















Figure 2: Receiver operating characteristic (ROC) curve for fecal
RPS19. The points on the curve represent the relative mRNA levels
of RPS19 in the feces and the sensitivity and (1-speciﬁcity) of the































Figure 3: The Kaplan-Meier overall survival curves in patients with
colorectal cancer according to fecal RPS19. The relative mRNA
levels of RPS19 in the feces are stratiﬁed into two groups: RPS19−
(<2.76 × 10−5) and RPS19+ (≥2.76 × 10−5). The six-year overall
survival rate of the RPS19+ group (n = 62) is better than that of the
RPS19− group (P = 0.008, log-rank test).
RPS19− (<2.76 × 10−5), using ROC curve analysis. The area
undertheROCcurveforfecalRPS27Lwas0.657(P = 0.012)
with a 95% CI of 0.556 to 0.749 (Figure 2). As shown in
Figure 3, the RPS19+ group (n = 62) had the better six-year
overall survival rate (74.3 ± 12.2%) than the RPS19− group
did (40.9 ±14.2%; n = 39) (P = 0.008, log-rank test).
To correlate the cellular function of RPS19, we infected
lentiviruses into a colonic cell line with wild-type p53









































Figure 4: Eﬃciency of RPS19 silence in colonic cells by RNA
interference. RPS19 silence is achieved by the lentivirus-mediated
RNAi experiment. Relative mRNA levels of RPS19 are quantiﬁed by
qRT-PCR with TaqMan probes and normalized by individual level
of 18s rRNA. The relative expression level of shLuc-infected cells is
considered as 1. Results are representative of those obtained in two-
to-three separate experiments with error bars showing standard
error. Changes of protein levels are immunoblotted with antibodies




































Figure 5: Changes of BAX expression in RPS19-silent colonic cells.
Relative mRNA levels of BAX are quantiﬁed by qRT-PCR with
TaqMan probes and normalized by individual level of 18s rRNA.
The relative expression level of shLuc-infected cells is considered as
1. Results are representative of those obtained in one experiment.
control shRNA (shLuc). In the lentivirus-mediated RNAi
experiment, shRPS19 achieved eﬃcient knockdown at both
the levels of mRNA and RPS19 protein (Figure 4). These
RPS19-silent cells expressed only 9.2% BAX mRNA from
RPS19-expressing cells compared to that from RPS19-
expressing cells (Figure 5).
4. Discussion
Our previous results revealed that numerous fecal molecules
were diﬀerentially expressed in the feces of CRC patients
[26]. Among the fecal molecules, a number of RP genes were
listed with statistic signiﬁcance [23]. RPs are involved not
only in the cellular process of translation [27] but also in the
growth and maintenance of all cell types [28]. Additionally,
numerous reports emphasized that a strong correlation was
found between RPs and p53 protein in cellular functions [17,
18, 29]. For example, RPL26 can regulate the translation and
induction of p53 after DNA damage [30]. RPS6 participated
in the activation of a p53-dependent cell cycle checkpointISRN Gastroenterology 5
[31]. RPS27L was proven to be a p53-inducible modulator of
cell fate in response to genotoxic stress [32], and mutant p53
seemed to cause aberrant RPS27L expression, which can lead
to the accumulation of tumorigenic CRC cells and a poor
prognosis [19].
Besides the p53-associated RPs, other RPs were also re-
vealed to contribute to the onset of cancer or multidrug re-
sistance [33–35]. For example, RPS3 is involved in the onset
of cancer [33], RPS13 and RPL23 promote the multidrug
resistance of gastric cancer cells [35], and RPL19 is involved
in the prognosis of prostate cancer and CRC [23, 36].
Recently, the direct relationship between feces and colonic
cells was proven [37, 38]. When combined, detecting fecal
RPs, speciﬁcally p53-related RPs, might be valuable for
evaluating the molecular pathogenesis of CRC [14, 15, 39].
In this study, the overall survival data revealed that
CRC patients with higher fecal expressions of RPS19 had
a better prognosis. When RPS19 was knocked down in co-
lonic cells, an apoptotic gene (BAX) extremely reduced the
expressions in RPS19-silent cells. Nevertheless, most studies
of RPS19 examined mutations in the RPS19 gene in patients
with Diamond-Blackfan anemia [40, 41]. Cells with an
RPS19 deﬁciency correlate with p53 dysregulation, which
may cause developmental anomalies [24]. To our knowledge,
we are the ﬁrst to reveal the diﬀerentially expressed RPS19
in CRC with clinical signiﬁcance. From the results of con-
sistentexpressionsofRPS19andBAX,wesuggestthatdown-
regulated RPS19 might impair the apoptotic function of
colonic cells. This argument supports the clinical data that
CRC patients with lower fecal expressions of RPS19 had a
poor prognosis.
5. Conclusions
We succeeded in quantifying the mRNA level of RPS19 in
feces. The potential mechanism of RPS19 in CRC possibly
involves cellular apoptosis through the BAX/p53 pathway
[42]. Our results provide some evidence that the levels of
fecal RPS19 may function as a prognostic predictor for CRC
patients. Finally, clinical use of feces in translational research
is promising for the future of CRC diagnosis [43].
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